Cytek Biosciences Past Earnings Performance
Past criteria checks 0/6
Cytek Biosciences's earnings have been declining at an average annual rate of -24.5%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 23% per year.
Key information
-24.5%
Earnings growth rate
44.5%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 23.0% |
| Return on equity | -3.1% |
| Net Margin | -6.3% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Cytek Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 193 | -12 | 92 | 44 |
| 30 Sep 23 | 183 | -14 | 89 | 43 |
| 30 Jun 23 | 176 | -6 | 83 | 41 |
| 31 Mar 23 | 166 | -2 | 75 | 37 |
| 31 Dec 22 | 164 | 2 | 68 | 35 |
| 30 Sep 22 | 155 | -1 | 63 | 32 |
| 30 Jun 22 | 148 | -3 | 59 | 30 |
| 31 Mar 22 | 139 | -2 | 52 | 27 |
| 31 Dec 21 | 128 | 0 | 46 | 24 |
| 30 Sep 21 | 120 | 1 | 37 | 22 |
| 30 Jun 21 | 110 | 2 | 31 | 19 |
| 31 Mar 21 | 99 | 4 | 27 | 16 |
| 31 Dec 20 | 93 | 3 | 24 | 14 |
| 31 Dec 19 | 58 | -17 | 17 | 9 |
Quality Earnings: CTKB is currently unprofitable.
Growing Profit Margin: CTKB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CTKB is unprofitable, and losses have increased over the past 5 years at a rate of 24.5% per year.
Accelerating Growth: Unable to compare CTKB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CTKB is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.6%).
Return on Equity
High ROE: CTKB has a negative Return on Equity (-3.09%), as it is currently unprofitable.